GlaxoSmithKline said Wednesday it has invested $120 million to expand its manufacturing facility in Upper Merion. The expansion took place at its east campus. GSK said in a statement its goal in Upper Merion was to create a "technologically-advanced manufacturing hub that offers the flexibility and speed necessary when making today’s complex specialty medicines.… With R&D and manufacturing using the same equipment, data, and analytics, we are creating efficiencies that will significantly reduce the overall time to produce a new medicine." The Upper Merion facility will initially be producing new drug candidates in clinical trials. Source: Bizjournals 26/9/2019